Recent policies reflect China’s goal of promoting patients’ access to innovative drugs. Noteworthy policy items include:

  • State Council released the Plan for Reforming the Division of Fiscal Administration Power and Expenditure Responsibilities between the Central and Local Level in the Area of Healthcare
  • China’s Politburo Held a Meeting Regarding Changchun Changsheng Biotechnology Ltd.’s Substandard Vaccines and Announced Disciplinary Action against Involved Officials
  • CDE released the List of Innovative Drugs with Urgent Clinical Need that have been Approved Overseas for public comment
  • NMSB DG Hu Jinglin visited Shanghai and called for effective implementation of pilot projects for centralized procurement of drugs


The latest issue could be downloaded Here >>

Leave a comment